Clinical Trials Logo

Operable Breast Neoplasms clinical trials

View clinical trials related to Operable Breast Neoplasms.

Filter by:
  • None
  • Page 1

NCT ID: NCT04985253 Active, not recruiting - Clinical trials for Operable Breast Neoplasms

Correlation of Predictive Accuracy of PREDICT Version 2.2 of Indian Women With Operable Breast Cancer

PREDICT
Start date: November 15, 2018
Phase:
Study type: Observational

This is an observational retrospective study which aims at comparing the 5-year survival estimates from "PREDICT V2.2" with observed 5-year outcome from our dataset of Indian women treated for operable breast cancer. "PREDICT V2.2" is a prognostication and treatment benefit tool developed in the UK. It is a tool available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions, for operable breast cancer patients. We hypothesize that 5-year overall survival (OS) predictions using "PREDICT V2.2" will have reasonable accuracy and applicability to the Indian operable breast cancer patients. The predictions, if accurate, will not only reassure the patients of the benefits of the treatment being offered, which outweigh the side effects but it will also make clinician as well as patient confident about avoiding potentially toxic systemic therapies, where the benefit is too small.

NCT ID: NCT00908531 Terminated - Clinical trials for Operable Breast Neoplasms

Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer

REAL
Start date: May 2009
Phase: Phase 3
Study type: Interventional

The hypothesis to be addressed in this randomized phase III trial is that 4 months of letrozole may be superior to surgery as primary therapy for early stage hormone receptor positive breast cancer in postmenopausal women, provided that these patients will receive definitive and radical surgery and adjuvant therapies as otherwise indicated at the completion of preoperative letrozole.